Cishe-umdlavuza / ukwelashwa / ukuhlolwa kwezilingo / izifo / i-intraocular-melanoma / ukwelashwa

Ukwelashwa Izilingo Zomtholampilo Ye-Intraocular Melanoma

Ukuhlolwa kwemitholampilo kuyizifundo zocwaningo ezibandakanya abantu. Ukuhlolwa kwemitholampilo kulolu hlu kungokwelashwa kwe-intraocular melanoma. Zonke izilingo ohlwini zisekelwa yi-NCI.

Imininingwane eyisisekelo ye-NCI mayelana nokuhlolwa komtholampilo ichaza izinhlobo nezigaba zezilingo nokuthi zenziwa kanjani. Ukuhlolwa komtholampilo kubheka izindlela ezintsha zokuvimbela, ukuthola, noma ukwelapha izifo. Ungahle uthande ukucabanga ngokubamba iqhaza esivivinyweni somtholampilo. Khuluma nodokotela wakho ngosizo lokunquma ukuthi ngabe kukulungele yini.

Izilingo 1-25 kwezingu-25

Ukuphepha nokusebenza kwe-IMCgp100 Ukuqhathanisa Nenketho Yomphenyi ku-Advanced Uveal Melanoma

Ukuhlola ukusinda okuphelele kwe-HLA-A * 0201 yeziguli zabantu abadala abane-UM esezingeni eliphakeme eyayingalashwa ngaphambili ethola i-IMCgp100 uma kuqhathaniswa ne-Investigator's Choice ye-dacarbazine, ipilimumab, noma i-pembrolizumab.

Indawo: izindawo eziyi-19

Isifundo se-XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

Lesi yisigaba 1, umthamo omningi, ucwaningo lokukhuphuka komthamo kanye nocwaningo lokukhulisa olwenzelwe ukuchaza umthamo obekezelelwe kakhulu kanye / noma umthamo onconyiwe we-XmAb22841 monotherapy futhi uhlanganiswe ne-pembrolizumab; ukuhlola ukuphepha, ukubekezelelana, i-pharmacokinetics, i-immunogenicity, nomsebenzi we-anti-tumor we-XmAb22841 monotherapy futhi uhlanganiswe ne-pembrolizumab ezifundweni ezinamathumba aqinile akhethiwe akhethiwe.

Indawo: izindawo eziyi-10

Ukufundwa kwe-RP1 Monotherapy ne-RP1 ngokuhlanganiswa neNivolumab

I-RPL-001-16 iyi-Phase 1/2, ilebula evulekile, ukukhuphuka komthamo nokwandiswa kokufundwa komtholampilo kwe-RP1 kuphela futhi kuhlanganiswe ne-nivolumab ezifundweni zabantu abadala ezinezicubu eziqinile ezithuthukisiwe kanye / noma eziphikisayo, ukuthola isilinganiso esiphezulu sokubekezelela (MTD) kanye nomthamo wesigaba 2 onconyiwe (RP2D), kanye nokuhlola ukusebenza kokuqala.

Indawo: izindawo ezi-6

Funda ngezihloko ezine-Melanoma Encane Eyinhloko Ye-Choroidal

Inhloso eyinhloko ukuhlola ukuphepha, ukungasebenzi komzimba kanye nokusebenza kwelinye lamazinga amathathu wethamo bese uphinda izinhlobo zemithamo ye-Light-activated AU-011 kanye nesicelo esisodwa noma ezimbili se-laser sokwelashwa kwezihloko ezine-choroidal melanoma eyinhloko.

Indawo: 4 izindawo

Ukufundwa kwe-IDE196 Ezigulini Ezinamaqhubu Aqinile Ukugcina Izinguquko ze-GNAQ / 11 noma i-PRKC Fusions

Lesi isigaba se-1/2, isikhungo esiningi, esinelebuli evulekile elenzelwe ukuhlola umsebenzi wezokuphepha nowokulwa nesimila we-IDE196 ezigulini ezinamathumba aqinile agcina ukuguqulwa kwe-GNAQ noma kwe-GNA11 (GNAQ / 11) noma ukuhlangana kwe-PRKC, kufaka phakathi i-metastatic i-uveal melanoma (MUM), i-melanoma enqenqemeni, umdlavuza obala kakhulu, nezinye izicubu eziqinile. Isigaba 1 (ukukhuphuka komthamo) kuzohlola ukuphepha, ukubekezelela kanye ne-pharmacokinetics ye-IDE196 ngesikimu sokukhuphuka komthamo ojwayelekile bese kunqunywa umthamo wesigaba 2 onconyiwe. Umsebenzi wezokuphepha nowokulwa nesimila uzohlolwa engxenyeni yeSigaba 2 (yokwandiswa kwedosi) yocwaningo.

Indawo: 4 izindawo

I-Selumetinib Sulfate Ekwelapheni Iziguli ezine-Uveal Melanoma noma i-GNAQ / GNA11 Mutated Melanoma Eyi-Metastatic noma Engenakususwa Ngokwehlinzwa

Lesi sigaba sesivivinyo se-Ib sihlola imiphumela engemihle kanye nomthamo omuhle we-selumetinib sulfate ekwelapheni iziguli ezine-uveal melanoma noma i-GNAQ / GNA11 mutated melanoma eye yasabalala isuka endaweni yokuqala iye kwezinye izindawo emzimbeni noma ingenakususwa ngokuhlinzwa. I-Selumetinib sulfate ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: izindawo ezi-3

I-Modified Virus VSV-IFNbetaTYRP1 ekwelapheni iziguli ezine-Stage III-IV Melanoma

Lesi sigaba sokuhlolwa kwesilingo sicwaninga ngemiphumela emibi kanye nomthamo omuhle wegciwane eliguquliwe elibizwa nge-VSV-IFNbetaTYRP1 ekwelapheni iziguli ezine-melanoma yesigaba III-IV. Igciwane le-vesicular stomatitis (i-VSV) lishintshiwe ukuze lifake izakhi zofuzo ezimbili ezingeziwe: i-human interferon beta (hIFNbeta), engavikela amangqamuzana avamile anempilo ekuthelelekeni ngaleli gciwane, kanye ne-TYRP1, evezwa ikakhulukazi kuma-melanocyte (iseli elikhethekile lesikhumba ikhiqiza i-melanin pigment melanin evikelayo yesikhumba) namaseli we-melanoma tumor, futhi kungadala ukuphendula okuqinile kokuzivikela komzimba ukubulala amangqamuzana e-melanoma tumor.

Indawo: izindawo ezi-2

Isifundo se-PLX2853 kuma-Malignancies athuthukile.

Inhloso yalolu cwaningo ukuhlola ukuphepha, i-pharmacokinetics, i-pharmacodynamics nokusebenza kokuqala kwesidakamizwa sokuphenya i-PLX2853 ezifundweni ezinokulimaza okuthuthukile.

Indawo: izindawo ezi-2

I-Yttrium90, i-Ipilimumab, ne-Nivolumab ye-Uveal Melanoma Enesibindi SeMetastases

Imibiko kuze kube manje ikhombisa ukusebenza okulinganiselwe kwe-immunotherapy ye-uveal melanoma. Ubufakazi bakamuva bokuhlola nobemitholampilo busikisela ukusebenzisana phakathi kokwelashwa ngemisebe kanye ne-immunotherapy. Abaphenyi bazobheka lokhu kusebenzisana ngokuhlola okungenzeka kweziguli ezingama-26 ezine-uveal melanoma kanye ne-hepatic metastases ezothola i-SirSpheres Yttrium-90 ekhetha imisebe yangaphakathi ye-hepatic elandelwa yi-immunotherapy ngokuhlanganiswa kwe-ipilimumab ne-nivolumab.

Indawo: izindawo ezi-2

I-Pegargiminase, i-Nivolumab ne-Ipilimumab ekwelapheni iziguli ezine-Uveal Melanoma Ethuthukile noma Enganqandeki

Lesi sigaba sokuhlolwa kwesigaba sokuqala sihlola imiphumela emibi ye-pegargiminase, i-nivolumab ne-ipilimumab ekwelapheni iziguli ezine-uveal melanoma ezisabalalele kwezinye izindawo emzimbeni (ezithuthukile) noma ezingenakususwa ngokuhlinzwa (okungenakulinganiswa). I-Pegargiminase ingamisa ukukhula kwamangqamuzana e-tumor ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab ne-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Ukunikeza i-pegargiminase, i-nivolumab ne-ipilimumab kungaba ngcono uma kuqhathaniswa ne-immunotherapy kuphela.

Indawo: Isikhumbuzo Somdlavuza We-Kettering Memorial, eNew York, eNew York

Ukwelashwa Kwemisebe Yomzimba We-Stereotactic kanye ne-Aflibercept ekwelapheni iziguli ezine-Uveal Melanoma

Isivivinyo sesigaba sesi-II sifundisisa ukuthi ukwelashwa ngemisebe ye-stereotactic radiation kanye nokusebenza kwe-aflibercept ekwelapheni iziguli ezine-uveal melanoma. Ukwelashwa kwemisebe yomzimba we-stereotactic kusebenzisa imishini ekhethekile ukubeka isiguli nokuletha imisebe kwizicubu ngokunemba okuphezulu. Le ndlela ingabulala amangqamuzana e-tumor ngemithamo embalwa esikhathini esifushane futhi ibangele ukulimala okuncane kwizicubu ezijwayelekile. I-Aflibercept ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli. Ukunikeza ukwelashwa ngemisebe yomzimba okulandelwa yi-aflibercept kungasebenza kangcono ekwelapheni iziguli ezine-uveal melanoma.

Indawo: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Isifundo Sokuphepha Nokubekezelela se-INCAGN02390 ku-Select Advanced Malignancies

Inhloso yalolu cwaningo ukucacisa ukuphepha, ukubekezelelana, nokusebenza kwangaphambi kokuqala kwe-INCAGN02390 kubahlanganyeli abanezimpawu ezimbi ezithuthukile ezikhethiwe.

Indawo: IHackensackack University Medical Center, iHackensack, eNew Jersey

Umuthi Wokugoma (6MHP) onayo noma ongenayo i-CDX-1127 yokwelashwa kwe-Stage IIB-IV Melanoma

Lesi sigaba sesivivinyo se-I / II sihlola imiphumela engemihle nokuthi umuthi wokugoma (6MHP) usebenza noma ungenayo i-CDX-1127 ekwelapheni i-melanoma yesigaba IIB-IV. Imithi yokugoma, efana ne-6MHP, ingasiza umzimba ukwakha impendulo ephumelelayo yokuvikela omzimba ukubulala amangqamuzana e-tumor. I-Immunotherapy enama-antibody monoclonal, njenge-CDX-1127, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale. Leli cala lenzelwa ukubona ukuthi yimiphi imiphumela i-6MHP iyodwa futhi ngokuhlangana ne-CDX-1127 enayo ekuguqukeni kumasosha omzimba.

Indawo: Isikhungo Somdlavuza saseYunivesithi yaseVirginia, eCharlottesville, eVirginia

I-Ipilimumab neNivolumab ene-Immunoembolization ekwelapheni iziguli ezine-Metastatic Uveal Melanoma esibindi

Lesi sigaba sesivivinyo sesi-II sicwaninga i-ipilimumab ne-nivolumab nge-immunoembolization ekwelapheni iziguli ezine-uveal melanoma eselusakaze esibindini. I-Immunotherapy enama-antibody monoclonal, njenge-ipilimumab ne-nivolumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa ikhono lamangqamuzana e-tumor ukukhula nokukhula. Ukwehliswa komzimba kungabulala amangqamuzana e-tumor ngenxa yokulahleka kokutholakala kwegazi futhi kuthuthukise ukuphendula komzimba ekulweni namaseli we-tumor. Ukunikeza i-ipilimumab ne-nivolumab nge-immunoembolization kungasebenza kangcono ekwelapheni iziguli ezine-uveal melanoma.

Indawo: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

I-Cyclophosphamide, i-Fludarabine, i-Tumor infiltrating Lymphocyte, ne-Aldesleukin ekwelapheni abahlanganyeli nge-Metastatic Uveal Melanoma

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-cyclophosphamide, i-fludarabine, isimila singena kanjani kuma-lymphocyte, kanye ne-aldesleukin isebenza ekwelapheni ababambiqhaza abane-uveal melanoma eye yasakazekela kwezinye izindawo emzimbeni. Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-cyclophosphamide ne-fludarabine, zisebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ama-tumor, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni. Ama-lymphocyte angena ngamathumba angaba ukwelashwa okuphumelelayo kwe-uveal melanoma. I-Aldesleukin ingashukumisa amangqamuzana amhlophe egazi ukuba abulale amaseli e-uveal melanoma. Ukunikeza i-cyclophosphamide, i-fludarabine, ama-lymphocyte afaka isimila, ne-aldesleukin kungabulala amangqamuzana amaningi wesimila.

Indawo: I- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

I-Autologous CD8 + SLC45A2-Specific T Lymphocyte ene-Cyclophosphamide, Aldesleukin, ne-Ipilimumab ekwelapheni abahlanganyeli nge-Metastatic Uveal Melanoma

Lesi sigaba sesivivinyo se-Ib sihlola imiphumela emibi kanye nomthamo omuhle kakhulu we-autologous CD8 positive (+) SLC45A2-specific T lymphocytes lapho unikezwa kanye ne-cyclophosphamide, aldesleukin, ne-ipilimumab, nokubona ukuthi basebenza kahle kanjani ekwelapheni ababambiqhaza abane-uveal melanoma esesabalele kwezinye izindawo emzimbeni. Ukwenza amaseli akhethekile e-CD8 + T, abacwaningi bahlukanisa amaseli we-T aqoqwe egazini lababambiqhaza futhi awaphathe ukuze akwazi ukukhomba amaseli e-melanoma. Amaseli egazi abese ebuyiselwa kumhlanganyeli. Lokhu kwaziwa ngokuthi "ukudluliswa kwamaseli okwamukela okwamukelwa ngu-T" noma "ukwelashwa kwe-T cell okwamukelayo." Izidakamizwa ezisetshenziselwa ukwelashwa ngamakhemikhali, njenge-cyclophosphamide, zingasebenza ngezindlela ezehlukene ukunqanda ukukhula kwamangqamuzana ama-tumor, kungaba ngokubulala amaseli, ngokuwavimba ekuhlukaniseni, noma ngokuwavimba ekusabalaleni. Imithi yokwelashwa, njenge-aldesleukin, sebenzisa izinto ezenziwe ngezinto eziphilayo ezingashukumisa amasosha omzimba ngezindlela ezahlukahlukene futhi amise amangqamuzana e-tumor ekukhuleni. I-Immunotherapy enama-antibody monoclonal, njenge-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale. Ukunikeza ama-lymphocyte e-CD8 + SLC45A2 aqondene ngqo ne-cyclophosphamide, aldesleukin, ne-ipilimumab kungasebenza kangcono ekwelapheni ababambiqhaza nge-metastatic uveal melanoma.

Indawo: MD Anderson Cancer Center, eHouston, Texas

I-Nivolumab efakwa ngaphakathi kanye ne-Intrathecal ekwelapheni iziguli ezinezifo ze-Leptomeningeal

Lesi sigaba sesivivinyo se-I / Ib sihlola imiphumela emibi kanye nomthamo omuhle we-intrathecal nivolumab, nokuthi isebenza kahle kanjani ngokuhlangana ne-nivolumab emthanjeni ekwelapheni iziguli ezinesifo se-leptomeningeal. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale.

Indawo: MD Anderson Cancer Center, eHouston, Texas

INivolumab ene-Ipilimumab noma engenayo noma i-Relatlimab ngaphambi kokuhlinzwa ekwelapheni iziguli ezine-Stage IIIB-IV Melanoma Engasuswa Ngokuhlinzwa

Lesi sivivinyo sesigaba II esingahleliwe sihlola ukuthi i-nivolumab ine-ipilimumab noma ingenayo noma i-relatlimab kahle kangakanani ngaphambi kokuhlinzwa isebenza ekwelapheni iziguli ezinesifo se-IIIB-IV se-melanoma esingasuswa ngokuhlinzwa. I-Immunotherapy enama-antibody monoclonal, njenge-nivolumab, ipilimumab, ne-relatlimab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi angaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale. Ukunikeza i-nivolumab iyodwa noma ihlanganiswe ne-ipilimumab noma i-relatlimab ngaphambi kokuhlinzwa kungenza isimila sibe sincane futhi kunciphise inani lezicubu ezijwayelekile ezidinga ukususwa.

Indawo: MD Anderson Cancer Center, eHouston, Texas

I-6MHP Vaccine ne-Ipilimumab ekwelapheni iziguli ezine-Stage IIA-IV Melanoma

Lesi sigaba sesivivinyo se-I / II sihlola imiphumela emibi yomuthi wokugoma we-peptide we-6 we-melanoma (6MHP) kanye ne-ipilimumab nokubona ukuthi basebenza kahle kanjani ekwelapheni iziguli ezine-melanoma yesigaba IIA-IV. Imithi yokugoma eyenziwe ngama-peptide, njengomuthi wokugoma i-6MHP, ingasiza umzimba ukwakha impendulo ephumelelayo yokuvikela omzimba ukubulala amangqamuzana e-tumor. I-Immunotherapy enama-antibody monoclonal, njenge-ipilimumab, ingasiza amasosha omzimba ukuthi ahlasele umdlavuza, futhi ingaphazamisa amandla amangqamuzana e-tumor ukuthi akhule futhi asabalale. Akukaziwa ukuthi ukunikeza umuthi wokugoma i-6MHP kanye ne-ipilimumab kusebenza kangcono ekwelapheni iziguli ezine-melanoma.

Indawo: Isikhungo Somdlavuza saseYunivesithi yaseVirginia, eCharlottesville, eVirginia

I-Dabrafenib Mesylate, iTrametinib, kanye ne-6 Melanoma Helper Peptide Vaccine Ekwelapheni Iziguli ezine-Stage IIIB-IV Melanoma

Lesi sigaba sesivivinyo se-I / II sihlola imiphumela engemihle nokuthi i-dabrafenib mesylate, trametinib, kanye nomuthi wokugoma we-peptide womsizi we-6 we-melanoma usebenza ekwelapheni iziguli ezine-melanoma yesigaba IIIB-IV. I-Dabrafenib mesylate ne-trametinib kungamisa ukukhula kwamangqamuzana e-tumor ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli. Imithi yokugoma, efana nomuthi wokugoma i-melanoma helper peptide, owenziwe ngama-peptide atholakala kuma-protein we-melanoma, ungasiza umzimba ukuthi wakhe amasosha omzimba asebenzayo ukubulala amangqamuzana e-tumor aveza ama-antigen aqondene ne-melanoma. Ukunikeza umuthi wokugomela i-dabrafenib, i-trametinib, ne-6 ye-melanoma umsizi we-peptide kungasebenza kangcono ekwelapheni iziguli ezine-melanoma.

Indawo: Isikhungo Somdlavuza saseYunivesithi yaseVirginia, eCharlottesville, eVirginia

ISunitinib Malate noma iValproic Acid Ekuvikeleni iMetastasis ezigulini ezine-High-Risk Uveal Melanoma

Lesi sivivinyo sesigaba II esingahleliwe sihlola ukuthi i-sunitinib malate noma i-valproic acid isebenza kanjani ekuvimbeleni i-melanoma enobungozi obukhulu (iso) ekusakazekeni iye kwezinye izingxenye zomzimba. I-Sunitinib malate ingamisa ukudluliswa kwezimpawu zokukhula zibe ngamangqamuzana e-tumor futhi ivimbele la maseli ekukhuleni. I-Valproic acid ingashintsha ukushintshwa kwezakhi zofuzo ezithile ku-uveal melanoma futhi icindezele ukukhula kwesimila.

Indawo: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Izicubu Ezingena KumaLymphocyte kanye ne-High-Dose Aldesleukin ngamaseli we-Autologous Dendritic ekwelapheni iziguli ezineMetastatic Melanoma

Lesi sivivinyo sesigaba II esingahleliwe sihlola ukuthi isimila sokwelashwa singena kahle kanjani kuma-lymphocyte kanye ne-aldesleukin yedosi ephezulu enamaseli e-autologous dendritic asebenza ekwelapheni iziguli ezine-melanoma ezisabalalele kwezinye izindawo zomzimba. Imithi yokugoma eyenziwe ngamangqamuzana omuntu wesimila namaseli akhethekile egazi (amaseli e-dendritic) angasiza umzimba ukwakha impendulo ephumelelayo yokuzivikela ekubulaleni amangqamuzana e-tumor. I-Aldesleukin ingashukumisa amangqamuzana amhlophe egazi ukuba abulale amangqamuzana ezimila. Okwamanje akwaziwa ukuthi isimila sokwelashwa esifakela ama-lymphocyte kanye ne-aldesleukin yedosi ephezulu kuyasebenza kakhulu uma kunikezwa kanye noma ngaphandle kwamaseli we-dendritic ekwehliseni noma ekubambeni ukukhula kwe-melanoma. Izinzuzo zomtholampilo zokuthola ama-lymphocyte angena ngesisu (TIL) ngokuhlangana ne-B-Raf proto-oncogene, i-serine / threonine kinase (BRAF) inhibitor izocwaningwa, ezigulini ezinesifo esiqhubekayo (PD) ngokusebenzisa i-BRAF inhibitor ngaphambi kokwelashwa kwe-TIL. Isifo se-Leptomeningeal (LMD) ngeshwa ukukhula okuvamile ezigulini ezine-melanoma, ezinesibikezelo esibi kakhulu, okuguqulela ekusindeni kwamasonto onke kuphela. Ngendlela yenoveli yokuhlanganisa i-intrathecal TILs kanye ne-intrathecal interleukin (IL) -2, abacwaningi banethemba lokukhuthaza ukuzinza kwezifo zesikhathi eside noma ukuxolelwa kwe-LMD.

Indawo: MD Anderson Cancer Center, eHouston, Texas

IVorinostat Yokwelapha I-Class 2 High Risk Uveal Melanoma

Lesi sigaba sokuqala sokucwaninga sifundisisa ukuthi i-vorinostat isebenza kanjani ekwelapheni iziguli ezinengcuphe enkulu ye-uveal (eye) melanoma. Abaphenyi bathola ukuthi amangqamuzana e-uveal melanomas ahlukaniswe kakhulu abe yizinhlobo ezimbili: isigaba 1 nesigaba 2. Amaseli ekilasi 2 ajwayele ukuba nethuba eliphakeme lokuthuthela kwezinye izitho emzimbeni, kuyilapho amaseli wesigaba 1 ikakhulukazi ehlala iso. IVorinostat ingakwazi ukuguqula amaseli wesigaba 2 abe amaseli ohlobo olunolaka olungaphansi "ngokuvula" izakhi zofuzo ezisengqamuzaneni ezicindezela izicubu.

Indawo: I- University of Miami Miller School of Medicine-Sylvester Cancer Center, eMiami, eFlorida

Ulixertinib ekwelapheni iziguli ezine-Stage IV Uveal Melanoma

Lesi sivivinyo sesigaba II sihlola imiphumela emibi ye-ulixertinib nokuthi isebenza kahle kanjani ekwelapheni iziguli ezine-melanoma yesigaba IV. I-Ulixertinib ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: Bheka Izilingo Zemitholampilo.gov

IVorinostat ekwelapheni iziguli ezine-Metastatic Melanoma yeso

Lesi sigaba sesivivinyo sesi-II sihlola ukuthi i-vorinostat isebenza kahle kanjani ekwelapheni iziguli ezine-melanoma yeso eselisabalalele kwezinye izingxenye zomzimba. IVorinostat ingamisa ukukhula kwamangqamuzana wesimila ngokuvimba amanye ama-enzyme adingekayo ekukhuleni kwamaseli.

Indawo: Bheka Izilingo Zemitholampilo.gov